Valuation: Mosaic ImmunoEngineering, Inc.

Market Cap 616K 561K 517K 470K 883K 57.07M 928K 6.3M 2.5M 31.17M 2.31M 2.26M 97.83M P/E 2024
-5.39x
P/E 2025 -3.11x
Enterprise Value 2.28M 2.08M 1.91M 1.74M 3.26M 211M 3.43M 23.27M 9.25M 115M 8.55M 8.37M 362M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
11.32%
Yield 2024 *
-
Yield 2025 -
11-20 Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 CI
08-14 Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
05-20 Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-15 Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
04-14 Mosaic ImmunoEngineering, Inc. Auditor Raises 'Going Concern' Doubt CI
11-19 Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
25-08-19 Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
25-05-20 Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-04-15 Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
25-04-14 Mosaic ImmunoEngineering, Inc. Auditor Raises 'Going Concern' Doubt CI
24-11-19 Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
24-08-14 Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
24-07-25 Mosaic ImmunoEngineering, Inc. Announces Resignation of Carlton Johnson from the Board, the Audit Committee and Compensation Committee CI
1 week+446.67%
Current month+139.77%
1 month-1.50%
3 months+437.70%
6 months-52.79%
Current year+5.47%
1 week 0.08
Extreme 0.076
0.33
1 month 0.06
Extreme 0.06
0.33
Current year 0.05
Extreme 0.054
0.75
1 year 0.05
Extreme 0.054
0.75
3 years 0.05
Extreme 0.054
1.13
5 years 0.05
Extreme 0.054
3
10 years 0.05
Extreme 0.054
9.22
Manager TitleAgeSince
Chief Executive Officer 61 2020-08-30
Director TitleAgeSince
Director/Board Member 61 2020-08-20
Date Insider Type Main position Quantity % Market Cap. Importance
2/18/22 Others

Founder

0 0.0000%
2/18/22 Others

Chief Executive Officer

0 0.0000%
2/18/22 Others

Director

0 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+446.67%-45.33%-34.53% 616K
-2.49%-3.76%+50.31%+62.10% 63.66B
-0.63%-2.91%+6.20%+89.22% 58.56B
-2.37%-2.22%+22.87%+82.31% 54.19B
-2.19%-6.15%+11.92%+108.08% 44.66B
-1.89%-7.28%+13.22%+19.74% 40.51B
-0.93%-0.47%+19.73%+43.75% 36.27B
+1.11%-6.44%+130.68%+641.83% 34.89B
-0.80%+0.61%+77.26%+56.26% 32.26B
-2.17%+16.65%-29.21%+474.05% 31.01B
Average -1.24%-1.09%+25.77%+154.28% 40B
Weighted average by Cap. -1.48%-1.85%+32.16%+150.90%

Financials

2024 2025
Net sales - -
Net income -922K -840K -774K -704K -1.32M -85.38M -1.39M -9.42M -3.74M -46.63M -3.46M -3.39M -146M -688K -626K -577K -525K -985K -63.69M -1.04M -7.03M -2.79M -34.79M -2.58M -2.53M -109M
Net Debt 1.48M 1.35M 1.24M 1.13M 2.12M 137M 2.22M 15.09M 6M 74.73M 5.54M 5.43M 235M 1.66M 1.51M 1.4M 1.27M 2.38M 154M 2.5M 16.98M 6.75M 84.07M 6.24M 6.11M 264M
Projected Income Statement - Annual - Mosaic ImmunoEngineering, Inc.
Logo Mosaic ImmunoEngineering, Inc.
Mosaic ImmunoEngineering, Inc. is a development-stage biotechnology company focused on advancing and eventually commercializing immunotherapies for the treatment of cancer. The Company is focused on new product candidates and platforms to expand its pipeline based on a deep understanding of immunotherapies and its license agreements with University of California San Diego.
Employees
5
Date Price Change Volume
26-11-20 US$0.0851 +11.97% 12,041
26-11-17 US$0.0760 +26.67% 108
  1. Stock Market
  2. Stocks
  3. CPMV Stock